Emergent Stability Testing for HIV Adenoviral Vaccine Candidates
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, has issued a Notice of Intent to Sole Source for Emergent Stability Testing for HIV Adenoviral Vaccine Candidates. NIAID intends to award a firm-fixed price purchase order to Emergent Travel Health Inc. for the maintenance of critical Biologics Master Files. This is not a request for competitive proposals, but interested parties may submit capabilities statements by April 23, 2026.
Scope of Work
This acquisition is for the maintenance of Biologics Master File 018816 (HIV-1 Adenovirus Type 4-Vectored Vaccines) and Biologics Master File 14883 (Manufacture and Characterization of A549 Master Cell Bank). Emergent owns these master files, which are essential for NIAID to continue updating IND 030255. The work includes ensuring these files remain open and current, covering remaining stability timepoints (84, 96, 108, and 120-month) for BB-MF 018816, and annual report submissions for BB-MF 14883 through October 2029.
Contract & Timeline
- Type: Notice of Intent to Sole Source (Firm-Fixed Price Purchase Order)
- Set-Aside: N/A
- NAICS Code: 541714 – RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
- PSC: Q301 – MEDICAL – LABORATORY TESTING
- Period of Performance:
- Base: April 27, 2026 – March 31, 2027
- Option Year 1: April 1, 2027 – March 31, 2028
- Option Year 2: April 1, 2028 – March 31, 2029 Note: There is a lapse in performance from October 1, 2025, to April 26, 2026, which will be reinstated and included in the award pricing.
- Response Due: April 23, 2026, 12:00 PM EST
- Published: April 14, 2026
Response & Evaluation
This is a notice of intent to award on a sole source basis to Emergent Travel Health Inc. due to their ownership of the required Biologics Master Files. Firms that believe they can provide the required capability may submit a capabilities statement, including past performance, in writing. Responses will be evaluated solely to determine if the procurement can be conducted on a competitive basis. A determination not to compete is at the Government's discretion.
Additional Notes
Contact Linda Smith at Linda.smith2@nih.gov for additional information or to submit responses. The Government plans to award a contract within 14 days of this notice.